This is the November / December 2024 edition of Anchovy News. Here you will find articles concerning ICANN, the domain name industry and ...

On Tuesday, H.C. Wainwright reaffirmed a Buy rating and a $37.00 stock price target for Pharming Group (NASDAQ: PHAR), a $602 million market cap company that according to InvestingPro analysis appears ...

Pharming is paying $66.1 million to acquire Swedish biotech Abliva and its phase 2-stage med that the Dutch drugmaker believes has blockbuster potential with a type of mitochondrial disease.

The conference call presentation is available on the pharming.com website from 14:00 CET on December 16, 2024 A transcript will be made available on the pharming.com website in the days following the ...

The conference call presentation is available on the pharming website from 14:00 CET on December 16, 2024 A transcript will be made available on the pharming website in the days following the call.

Leiden, the Netherlands, December 15, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced a recommended public cash offer to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Leiden, the Netherlands, December 11, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces positive topline results of data from its Phase III ...

Pharming plans to include data from this 4-11-year-old trial in regulatory filings worldwide for the approval of leniolisib for pediatric patients with APDS, beginning in 2025. The study enrolled ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Pharming Group announced promising topline results from its Phase III clinical trial of leniolisib, targeting ...